Uproleselan sodium is a Small Molecule owned by GlycoMimetics, and is involved in 14 clinical trials, of which 7 were completed, and 7 are ongoing.
Uproleselan sodium (GMI-1271) is an E-Selectin (CD62E) inhibitor. Selectins are a family of transmembrane molecules, expressed on the surface of leukocytes and activated endothelial cells. E-selectin mediates the adhesion of tumor cells to endothelial cells, by binding to E-selectin ligands expressed by neutrophils, monocytes, eosinophils, memory-effector T-like lymphocytes, natural killer cells or cancer cells. The drug candidate antagonizes E-selectin and thereby it binds to E-selectin ligands.
The revenue for Uproleselan sodium is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Uproleselan sodium NPV Report.
Uproleselan sodium is originated and owned by GlycoMimetics.
Uproleselan sodium Overview
Uproleselan sodium (GMI-1271) is under the development for the treatment of acute myeloid leukemia (AML), coronavirus disease 2019 (COVID-19) pneumonia, myelodysplastic syndrome, chronic myelogenous leukemia and Inflammatory diseases. The drug candidate is administered through intravenous route. It acts by targeting E-selectin. GMI-1271 is a mimetic of naturally occurring carbohydrate (GlycoMimetics). It was also under development for deep venous thrombosis, pancreatic cancer, multiple myeloma and breast cancer.
GlycoMimetics is a clinical-stage biotechnology company that discovers, develops and commercializes small molecule drugs. The company’s pipeline products comprise uproleselan, rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. GlycoMimetics also designs galectin inhibitors for advancing treatment options of various diseases. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.
The company reported revenues of (US Dollars) US$1.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 88.6% over FY2020. The operating loss of the company was US$63.5 million in FY2021, compared to an operating loss of US$51.5 million in FY2020. The net loss of the company was US$63.4 million in FY2021, compared to a net loss of US$51 million in FY2020.
Quick View – Uproleselan sodium
|Highest Development Stage|